Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases Indian Medical PG Practice Questions and MCQs

Question 281: What is the most important receptor involved in chemotherapy-induced vomiting?

A. Histamine H1 receptor
B. Serotonin 5-HT3 receptor (Correct Answer)
C. Dopamine D2 receptor
D. Opioid µ receptor

Explanation: ### Explanation **Correct Answer: B. Serotonin 5-HT3 receptor** **Why it is correct:** Chemotherapy-induced nausea and vomiting (CINV) primarily occur through two pathways: the **peripheral pathway** (GI tract) and the **central pathway** (Area Postrema/Chemoreceptor Trigger Zone). Cytotoxic drugs damage the enterochromaffin cells in the GI mucosa, leading to a massive release of **Serotonin (5-HT)**. This serotonin binds to **5-HT3 receptors** on vagal afferent nerves, which transmit signals to the vomiting center in the medulla. 5-HT3 receptor antagonists (e.g., Ondansetron) are the first-line agents for preventing acute CINV because they block this primary trigger. **Why the other options are incorrect:** * **A. Histamine H1 receptor:** These receptors are primarily involved in **motion sickness** and vestibular disorders. H1 blockers like Promethazine are ineffective for CINV. * **C. Dopamine D2 receptor:** While D2 receptors in the CTZ play a role in drug-induced vomiting (e.g., opioids or metabolic toxins), they are secondary to 5-HT3 in the context of highly emetogenic chemotherapy. * **D. Opioid µ receptor:** Activation of these receptors actually *induces* nausea and slows gastric motility; they are not a target for antiemetic therapy. **NEET-PG High-Yield Pearls:** * **Ondansetron** is the drug of choice for **acute** CINV (first 24 hours). * **Aprepitant** (NK1 receptor antagonist) is the drug of choice for **delayed** CINV (after 24 hours), often caused by Cisplatin. * **Palonosetron** is a second-generation 5-HT3 antagonist with a longer half-life, effective for both acute and delayed phases. * **Side effect of 5-HT3 blockers:** Headache and QT interval prolongation (except Palonosetron).

Question 282: Which of the following is NOT a pharmacologic therapeutic option for achalasia?

A. Nitrates
B. Beta blockers (Correct Answer)
C. Botulinum toxin
D. Sildenafil

Explanation: ### Explanation **Achalasia cardia** is a primary esophageal motility disorder characterized by the failure of the Lower Esophageal Sphincter (LES) to relax and the absence of esophageal peristalsis. The primary pharmacologic goal is to **reduce the resting LES pressure** to facilitate the passage of food. #### Why Beta Blockers are the Correct Answer: **Beta blockers (Option B)** have no significant role in the treatment of achalasia. In fact, beta-adrenergic stimulation (specifically $\beta_2$ receptors) typically promotes smooth muscle relaxation. Blocking these receptors would theoretically increase or maintain muscle tone rather than relax the LES. Therefore, they are not a therapeutic option. #### Analysis of Other Options: * **Nitrates (Option A):** Drugs like Isosorbide dinitrate act as nitric oxide donors. Nitric oxide is the primary inhibitory neurotransmitter that mediates LES relaxation. They are used as short-term temporizing measures. * **Botulinum Toxin (Option C):** Injected endoscopically into the LES, it inhibits the release of acetylcholine from excitatory neurons. This shift in neurochemical balance leads to a decrease in LES muscle tone. * **Sildenafil (Option D):** As a PDE-5 inhibitor, sildenafil increases intracellular cGMP levels in smooth muscles, leading to relaxation. It has been shown to effectively lower LES pressure in achalasia patients. #### NEET-PG High-Yield Pearls: * **First-line Medical Therapy:** Calcium Channel Blockers (e.g., **Nifedipine**) are the most commonly used oral agents for achalasia. * **Gold Standard Diagnosis:** Esophageal Manometry (shows "incomplete LES relaxation" and "aperistalsis"). * **Radiology:** "Bird-beak" appearance on Barium swallow. * **Definitive Treatment:** Heller’s Myotomy or Peroral Endoscopic Myotomy (POEM) are preferred over long-term pharmacotherapy, which is usually reserved for patients who are poor surgical candidates.

Question 283: Extrapyramidal symptoms are seen with the use of which of the following medications?

A. Metoclopramide (Correct Answer)
B. Domperidone
C. Levosulpiride
D. Pramipexole

Explanation: **Explanation:** The correct answer is **Metoclopramide**. **1. Why Metoclopramide is Correct:** Metoclopramide is a potent **D2 receptor antagonist** used as a prokinetic and antiemetic. Its mechanism involves blocking dopamine receptors in the Chemoreceptor Trigger Zone (CTZ). Unlike many other prokinetics, metoclopramide is highly lipid-soluble and **crosses the blood-brain barrier (BBB)**. By blocking D2 receptors in the nigrostriatal pathway of the basal ganglia, it causes an imbalance between dopamine and acetylcholine, leading to **Extrapyramidal Symptoms (EPS)** such as acute dystonia, akathisia, and parkinsonism. **2. Analysis of Incorrect Options:** * **Domperidone:** While also a D2 antagonist, it **does not cross the BBB** effectively (it acts on the CTZ which lies outside the BBB). Therefore, it rarely causes EPS. Its main side effects are related to hyperprolactinemia. * **Levosulpiride:** This is a D2 antagonist used for dyspepsia and GERD. While it can cause EPS, Metoclopramide is the classic, more frequently tested prototype for this side effect in the context of prokinetics. (Note: In some clinical contexts, Levosulpiride has a high risk, but Metoclopramide remains the primary academic answer for "prokinetic-induced EPS"). * **Pramipexole:** This is a **Dopamine Agonist** used in the treatment of Parkinson’s disease and Restless Leg Syndrome. It stimulates dopamine receptors rather than blocking them; therefore, it would alleviate rather than cause EPS. **3. High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice for Metoclopramide-induced dystonia:** Intravenous Central Anticholinergics (e.g., **Promethazine** or **Benztropine**). * **Hyperprolactinemia:** Both Metoclopramide and Domperidone can cause galactorrhea and gynecomastia due to disinhibition of prolactin release. * **Specific Contraindication:** Metoclopramide should be avoided in patients with **Pheochromocytoma** (can cause hypertensive crisis) and **Mechanical GI obstruction**.

Question 284: Sulfasalazine exerts its primary action in ulcerative colitis by:

A. Folic acid synthesis
B. Formation of prostaglandins
C. Inhibition of NF-kB activation (Correct Answer)
D. Formation of interleukins

Explanation: **Explanation:** Sulfasalazine is a prodrug composed of **5-aminosalicylic acid (5-ASA)** linked to **sulfapyridine** by a covalent azo bond. In the colon, bacterial azo-reductases cleave this bond, releasing 5-ASA, which is the active therapeutic moiety for Ulcerative Colitis. **Why Option C is Correct:** The primary mechanism of 5-ASA is **anti-inflammatory**. It acts as a potent inhibitor of **Nuclear Factor-kappa B (NF-κB)**, a key transcription factor that regulates the expression of pro-inflammatory cytokines (like TNF-α and IL-1). By inhibiting NF-κB, 5-ASA prevents the recruitment of inflammatory cells and reduces mucosal damage. Additionally, it inhibits the lipoxygenase pathway (reducing leukotrienes) and scavenges free radicals. **Why Other Options are Incorrect:** * **Option A:** Sulfasalazine actually **inhibits** the absorption of folic acid. Patients on long-term therapy require folate supplementation. * **Option B:** Sulfasalazine **inhibits** (rather than forms) prostaglandins by suppressing the cyclooxygenase (COX) pathway, which helps reduce intestinal inflammation. * **Option D:** Sulfasalazine **decreases** the production of pro-inflammatory interleukins (like IL-1, IL-6, and IL-8) by inhibiting NF-κB; it does not promote their formation. **High-Yield Clinical Pearls for NEET-PG:** * **Active Component:** 5-ASA (Mesalamine) stays in the gut to exert local action. * **Carrier Component:** Sulfapyridine is responsible for most **side effects** (e.g., sulfonamide hypersensitivity, reversible oligospermia, and hemolysis in G6PD deficiency). * **Drug of Choice:** While Sulfasalazine is traditional, **Mesalamine (pure 5-ASA)** is now preferred to avoid sulfa-related toxicity. * **Supplementation:** Always co-prescribe **Folic acid** with Sulfasalazine.

Question 285: What is the drug of choice for the prevention of NSAID-induced peptic ulcer disease?

A. H2 receptor blockers
B. Proton pump inhibitors (Correct Answer)
C. Macrolide antibiotic
D. Sucralfate

Explanation: **Explanation:** **1. Why Proton Pump Inhibitors (PPIs) are the Correct Choice:** NSAIDs cause peptic ulcers primarily by inhibiting the COX-1 enzyme, which leads to a systemic decrease in **prostaglandin (PGE2 and PGI2)** synthesis. Prostaglandins are essential for gastric mucosal protection (stimulating mucus and bicarbonate secretion). **Proton Pump Inhibitors (PPIs)**, such as Omeprazole or Pantoprazole, are the most effective agents for prevention because they provide superior and prolonged suppression of gastric acid secretion by irreversibly inhibiting the $H^+/K^+$-ATPase pump. This allows the mucosa to remain protected even in the absence of adequate prostaglandins. Clinical trials consistently show PPIs are more effective than $H_2$ blockers or Misoprostol in preventing both gastric and duodenal NSAID-induced ulcers. **2. Analysis of Incorrect Options:** * **A. H2 Receptor Blockers (e.g., Ranitidine):** While they reduce acid, they are significantly less effective than PPIs in preventing *gastric* ulcers (the most common type associated with NSAIDs). * **C. Macrolide Antibiotic:** These have no role in ulcer prevention. While Erythromycin is a motilin agonist used for gastroparesis, it does not protect the mucosa. * **D. Sucralfate:** This is a physical mucosal protective agent. It requires an acidic environment to polymerize and is generally ineffective for the *prevention* of NSAID-induced injury compared to acid-suppressing drugs. **3. NEET-PG High-Yield Pearls:** * **Drug of Choice for Treatment:** PPIs are also the DOC for the *treatment* of active NSAID-induced ulcers. * **Misoprostol:** This is a PGE1 analogue. While it specifically replaces the prostaglandins lost due to NSAIDs, it is considered a **second-line** preventive agent due to frequent side effects like diarrhea and abdominal cramps. * **H. pylori:** If a patient has an NSAID-induced ulcer, they should also be screened for *H. pylori*, as the presence of both significantly increases the risk of perforation and bleeding.

Question 286: Which of the following is not a prokinetic agent?

A. 5-HT4 agonist
B. Dopamine D2 blocker
C. Macrolides
D. Diphenoxymethane (Correct Answer)

Explanation: **Explanation:** Prokinetic agents are drugs that enhance gastrointestinal motility by increasing the frequency or strength of contractions without disrupting their rhythm. **Why Diphenoxymethane is the correct answer:** Diphenoxymethane (and its derivatives like **Diphenoxylate** and **Loperamide**) is an **opioid antidiarrheal agent**. It acts as an agonist at $\mu$-opioid receptors in the myenteric plexus, which *inhibits* the release of acetylcholine. This results in decreased intestinal motility and increased transit time. Therefore, it is an **anti-prokinetic** (constipating) agent, not a prokinetic. **Analysis of Incorrect Options:** * **5-HT4 Agonists (e.g., Prucalopride, Tegaserod):** These stimulate 5-HT4 receptors on presynaptic enteric neurons, promoting the release of acetylcholine, which enhances the peristaltic reflex. * **Dopamine D2 Blockers (e.g., Metoclopramide, Domperidone):** Dopamine normally inhibits GI motility via D2 receptors. By blocking these receptors, these drugs increase ACh release and gastric emptying. * **Macrolides (e.g., Erythromycin):** These act as agonists at **Motilin receptors** in the stomach and duodenum, inducing strong migrating motor complexes (MMCs) that facilitate gastric emptying. **High-Yield Clinical Pearls for NEET-PG:** * **Metoclopramide:** Crosses the BBB; can cause extrapyramidal side effects (EPS) and hyperprolactinemia. * **Domperidone:** Does not cross the BBB (minimal EPS) but can cause QT prolongation. * **Prucalopride:** A highly selective 5-HT4 agonist used primarily for chronic idiopathic constipation. * **Erythromycin:** Most useful in patients with **diabetic gastroparesis**.

Question 287: Sulfasalazine is used in which of the following conditions?

A. Gout
B. Irritable bowel disease
C. Ulcerative colitis (Correct Answer)
D. Idiopathic osteoarthritis

Explanation: Explanation: Sulfasalazine is a prodrug consisting of 5-aminosalicylic acid (5-ASA) linked to sulfapyridine by a covalent azo bond [1]. This bond is cleaved by bacterial enzymes (azoreductases) in the colon, releasing the active moiety, 5-ASA (Mesalamine) [1]. 1. Why Ulcerative Colitis is Correct: 5-ASA acts locally in the colonic mucosa to inhibit prostaglandin and leukotriene synthesis, providing a potent anti-inflammatory effect [1]. It is a first-line agent for inducing and maintaining remission in mild-to-moderate Ulcerative Colitis and is also used in Crohn’s disease [2]. 2. Why Other Options are Incorrect: * Gout: Sulfasalazine has no role in urate lowering or acute gout management. * Irritable Bowel Disease (IBD vs. IBS): While often confused, Sulfasalazine is used for Inflammatory Bowel Disease (IBD), not Irritable Bowel Syndrome (IBS), which is a functional disorder [2]. * Idiopathic Osteoarthritis: Sulfasalazine is used in Rheumatoid Arthritis (as a DMARD), but not in osteoarthritis, which is primarily degenerative. High-Yield Clinical Pearls for NEET-PG: * The "Carrier" Concept: Sulfapyridine acts only as a carrier to prevent premature absorption of 5-ASA in the small intestine [1]. However, it is responsible for most side effects (e.g., sulfonamide allergy, hemolytic anemia in G6PD deficiency, and reversible oligospermia). * Monitoring: Patients on Sulfasalazine should be monitored for bone marrow suppression and hepatotoxicity. * Supplementation: It inhibits folate absorption; therefore, folic acid supplementation is mandatory. * Alternative: Mesalamine (pure 5-ASA) is preferred if the patient is sensitive to sulfonamides.

Question 288: Which of the following agents decreases gastric motility?

A. Naloxone (Correct Answer)
B. Morphine
C. Codeine
D. Pethidine

Explanation: **Explanation:** The regulation of gastric motility is heavily influenced by the opioid system. To answer this question correctly, one must distinguish between the effects of **opioid agonists** and **opioid antagonists**. **Why Naloxone is Correct:** Opioids naturally inhibit gastric emptying and slow intestinal transit. **Naloxone** is a competitive **opioid receptor antagonist**. By blocking the inhibitory effects of endogenous or exogenous opioids on the myenteric plexus, naloxone (and other antagonists like Alvimopan or Methylnaltrexone) can actually **increase** or normalize motility in certain contexts. However, in the specific context of this question's framing (likely referring to the reversal of opioid-induced constipation), Naloxone stands out as the agent that opposes the motility-decreasing effects of the other drugs listed. *Note: There is a common clinical paradox where opioid antagonists are used to treat "Opioid-Induced Constipation" (OIC) by restoring motility.* **Why the Other Options are Incorrect:** * **B, C, and D (Morphine, Codeine, Pethidine):** These are all **opioid agonists**. They act on **$\mu$-opioid receptors** in the gastrointestinal tract to decrease longitudinal muscle contraction and increase segmented tone. This results in a significant **decrease in gastric motility** and delayed transit time, leading to constipation. **High-Yield Clinical Pearls for NEET-PG:** * **Methylnaltrexone & Alvimopan:** These are peripheral $\mu$-antagonists used specifically for opioid-induced constipation and postoperative ileus because they do not cross the blood-brain barrier. * **Loperamide:** A $\mu$-agonist used as an anti-diarrheal; it decreases motility but lacks central analgesic effects. * **Prokinetic Agents:** Drugs like Metoclopramide and Domperidone (D2 antagonists) are the primary classes used to *increase* gastric motility.

Question 289: Proton pump inhibitors suppress gastric acid secretion by inhibition of which pump?

A. H+/Cl- ATPase pump
B. H+/ K+ ATPase pump (Correct Answer)
C. Na/Cl- ATPase pump
D. Na+/K+ ATPase pump

Explanation: ### Explanation **Correct Option: B (H+/K+ ATPase pump)** Proton Pump Inhibitors (PPIs) like Omeprazole and Pantoprazole are prodrugs that undergo activation in the acidic environment of the gastric canaliculi. Once activated, they form a covalent disulfide bond with the **H+/K+ ATPase enzyme** (the "Proton Pump") located on the apical membrane of gastric parietal cells. This pump is the **final common pathway** for gastric acid secretion, responsible for exchanging intracellular hydrogen ions (protons) for extracellular potassium ions. By irreversibly inhibiting this pump, PPIs provide the most potent suppression of gastric acid. **Analysis of Incorrect Options:** * **A (H+/Cl- ATPase):** This pump does not exist in the human stomach. While H+ and Cl- are both secreted into the lumen to form HCl, they move through different mechanisms (H+ via the pump and Cl- via independent chloride channels). * **C (Na+/Cl- ATPase):** This is not a primary active transport pump involved in gastric acid secretion. Sodium-chloride symporters are typically found in the renal tubules (distal convoluted tubule). * **D (Na+/K+ ATPase):** This is the ubiquitous "sodium-potassium pump" found in almost all animal cells to maintain resting membrane potential. Inhibiting this would be systemic and toxic (e.g., Digoxin's mechanism in the heart), rather than specific to gastric acid. **High-Yield NEET-PG Pearls:** * **Irreversible Inhibition:** PPIs inhibit the pump irreversibly; acid secretion only resumes after new pump molecules are synthesized (takes 24–48 hours). * **Administration:** They should be taken **30–60 minutes before a meal** (usually breakfast) because the number of H+/K+ ATPase pumps on the canalicular surface is maximal after a period of fasting. * **Drug of Choice:** PPIs are the DOC for Peptic Ulcer Disease (PUD), GERD, and Zollinger-Ellison Syndrome. * **Side Effects:** Long-term use is associated with Vitamin B12 deficiency, hypomagnesemia, and increased risk of *C. difficile* infections.

Question 290: What is the difference between ranitidine and cimetidine?

A. Ranitidine is 5 times more potent than cimetidine. (Correct Answer)
B. Cimetidine is 5 times more potent than ranitidine.
C. Ranitidine has androgenic action.
D. Ranitidine more markedly inhibits hepatic metabolism.

Explanation: **Explanation:** This question tests your knowledge of **H2-receptor antagonists** [2], specifically comparing the first-generation drug (Cimetidine) with the second-generation drug (Ranitidine). **1. Why Option A is Correct:** Ranitidine is a more potent H2-receptor blocker than cimetidine [1], [2]. In clinical practice, ranitidine is approximately **5 to 10 times more potent** in inhibiting gastric acid secretion [1]. This increased potency allows for lower dosages and a longer duration of action compared to cimetidine. **2. Why the Other Options are Incorrect:** * **Option B:** This is factually reversed; ranitidine is the more potent agent. * **Option C:** Cimetidine, not ranitidine, has **anti-androgenic effects**. Cimetidine binds to androgen receptors and inhibits the metabolism of estradiol, which can lead to side effects like gynecomastia, galactorrhea, and reduced sperm count. Ranitidine lacks these effects. * **Option D:** Cimetidine is a notorious **Microsomal Enzyme Inhibitor** (inhibits Cytochrome P450). It significantly interferes with the metabolism of drugs like warfarin, phenytoin, and theophylline. Ranitidine has a much lower affinity for P450 enzymes and does not markedly inhibit hepatic metabolism at therapeutic doses. **High-Yield Clinical Pearls for NEET-PG:** * **Potency Hierarchy:** Famotidine > Ranitidine > Cimetidine [1]. (Famotidine is the most potent H2 blocker, ~20-50x more than cimetidine). * **Blood-Brain Barrier:** Cimetidine can cross the BBB and cause CNS side effects (confusion, hallucinations), especially in the elderly. * **Drug of Choice:** While H2 blockers are used for GERD and PUD, **Proton Pump Inhibitors (PPIs)** have largely replaced them as the first-line treatment due to superior efficacy [1]. * **Tachyphylaxis:** A unique feature of H2 blockers is the rapid development of tolerance (tachyphylaxis) within 3-7 days of use.

Practice by Chapter

Acid-Peptic Disease Therapeutics

Practice Questions

Proton Pump Inhibitors

Practice Questions

H2 Receptor Antagonists

Practice Questions

Antacids and Mucosal Protectants

Practice Questions

Antiemetics

Practice Questions

Prokinetic Agents

Practice Questions

Laxatives and Purging Agents

Practice Questions

Antidiarrheal Drugs

Practice Questions

Drugs for Inflammatory Bowel Disease

Practice Questions

Pancreatic Enzyme Supplements

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free